Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner

Iris Eke*, Molykutty J. Aryankalayil, Michelle A. Bylicky, Adeola Y. Makinde, Lance Liotta, Valerie Calvert, Emanuel F. Petricoin, Edward E. Graves, C. Norman Coleman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The efficacy of molecular targeted therapy depends on expression and enzymatic activity of the target molecules. As radiotherapy modulates gene expression and protein phosphorylation dependent on dose and fractionation, we analyzed the long-term effects of irradiation on the post-radiation efficacy of molecular targeted drugs. We irradiated prostate cancer cells either with a single dose (SD) of 10 Gy x-ray or a multifractionated (MF) regimen with 10 fractions of 1 Gy. Whole genome arrays and reverse phase protein microarrays were used to determine gene expression and protein phosphorylation. Additionally, we evaluated radiation-induced pathway activation with the Ingenuity Pathway Analysis software. To measure cell survival and sensitivity to clinically used molecular targeted drugs, we performed colony formation assays. We found increased activation of several pathways regulating important cell functions such as cell migration and cell survival at 24 h after MF irradiation or at 2 months after SD irradiation. Further, cells which survived a SD of 10 Gy showed a long-term upregulation and increased activity of multiple molecular targets including AKT, IGF-1R, VEGFR2, or MET, while HDAC expression was decreased. In line with this, 10 Gy SD cells were more sensitive to target inhibition with Capivasertib or Ipatasertib (AKTi), BMS-754807 (IGF-1Ri), or Foretinib (VEGFR2/METi), but less sensitive to Panobinostat or Vorinostat (HDACi). In summary, understanding the molecular short- and long-term changes after irradiation can aid in optimizing the efficacy of multimodal radiation oncology in combination with post-irradiation molecularly-targeted drug treatment and improving the outcome of prostate cancer patients.

Original languageEnglish
Article number3500
JournalScientific Reports
Issue number1
StatePublished - Dec 2022
Externally publishedYes


Dive into the research topics of 'Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner'. Together they form a unique fingerprint.

Cite this